CHT105 for the Treatment of Refractory Lupus Nephritis | MicrobiomeTrials← Back to trialsNCT07517536
CHT105 for the Treatment of Refractory Lupus Nephritis
ENROLLING_BY_INVITATIONNAINTERVENTIONAL
Trial Details
Start: 2026-04-22Est. Completion: 2028-01
Enrollment target: 14 participants Locations- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Other microbiome trials you might be interested in
Systemic Lupus ErythematosusImmune Thrombocytopenia
The goal of this clinical trial is to learn if sirolimus, added to standard background therapy (corticosteroids and hydr…
Beijing, ChinaEst. completion Sep 30, 2027
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030
Recruiting
Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)
Background:
Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. Peop…
Bethesda, United StatesEst. completion May 31, 2027